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Background: Randomised controlled trials (RCTs) exploring the potential of vitamin D to prevent acute
respiratory infections have yielded mixed results. Individual participant data (IPD) meta-analysis has the
potential to identify factors that may explain this heterogeneity.
Objectives: To assess the overall effect of vitamin D supplementation on the risk of acute respiratory
infections (ARIs) and to identify factors modifying this effect.
Data sources: MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials (CENTRAL), Web of
Science, ClinicalTrials.gov and the International Standard Randomised Controlled Trials Number (ISRCTN) registry.
Study selection: Randomised, double-blind, placebo-controlled trials of supplementation with vitamin D3
or vitamin D2 of any duration having incidence of acute respiratory infection as a prespecified efficacy
outcome were selected.
Study appraisal: Study quality was assessed using the Cochrane Collaboration Risk of Bias tool to assess
sequence generation, allocation concealment, blinding of participants, personnel and outcome assessors,
completeness of outcome data, evidence of selective outcome reporting and other potential threats
to validity.
Results: We identified 25 eligible RCTs (a total of 11,321 participants, aged from 0 to 95 years). IPD were
obtained for 10,933 out of 11,321 (96.6%) participants. Vitamin D supplementation reduced the risk of
ARI among all participants [adjusted odds ratio (aOR) 0.88, 95% confidence interval (CI) 0.81 to 0.96;
heterogeneity p < 0.001]. Subgroup analysis revealed that protective effects were seen in individuals
receiving daily or weekly vitamin D without additional bolus doses (aOR 0.81, 95% CI 0.72 to 0.91), but
not in those receiving one or more bolus doses (aOR 0.97, 95% CI 0.86 to 1.10; p = 0.05). Among those
receiving daily or weekly vitamin D, protective effects of vitamin D were stronger in individuals with a
baseline 25-hydroxyvitamin D [25(OH)D] concentration of < 25 nmol/l (aOR 0.30, 95% CI 0.17 to 0.53)
than in those with a baseline 25(OH)D concentration of ≥ 25 nmol/l (aOR 0.75, 95% CI 0.60 to 0.95;
p = 0.006). Vitamin D did not influence the proportion of participants experiencing at least one serious
adverse event (aOR 0.98, 95% CI 0.80 to 1.20; p = 0.83). The body of evidence contributing to these
analyses was assessed as being of high quality.
Limitations: Our study had limited power to detect the effects of vitamin D supplementation on the risk
of upper versus lower respiratory infection, analysed separately.
Conclusions: Vitamin D supplementation was safe, and it protected against ARIs overall. Very deficient
individuals and those not receiving bolus doses experienced the benefit. Incorporation of additional IPD from
ongoing trials in the field has the potential to increase statistical power for analyses of secondary outcomes.
Study registration: This study is registered as PROSPERO CRD42014013953.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Plain English summary
Research question
Does taking a vitamin D supplement help to prevent colds, flu and chest infections?
Background
Low blood levels of vitamin D (the ‘sunshine vitamin’) have been linked to an increased risk of colds, flu
and chest infections, collectively termed ‘acute respiratory infections’ (ARIs). Clinical trials testing whether
or not vitamin D supplements can prevent ARIs have had mixed results. The reason why vitamin D appears
to work in some situations but not others is not understood. In order to answer this question, we obtained
data from individuals who took part in previous clinical trials, combined them and analysed them to
answer two questions:
1. Does vitamin D reduce the overall risk of ARIs, broadly defined?
2. Do some people benefit more from taking vitamin D than others?
Included studies
We obtained raw data on a total of 10,933 people from 25 trials conducted in 15 countries. Participants
were aged from 0 to 95 years. All of the studies compared vitamin D with placebo (dummy medication),
which is the gold standard trial design.
Key results
Overall, vitamin D supplements reduced the risk of having at least one ARI from 42% to 39%. We also
showed that vitamin D had greater protective effects when it was given daily or weekly to people with the
lowest vitamin D levels: the risk of having at least one ARI was reduced from 60% to 32% in these
individuals. Vitamin D was not effective in protecting against ARIs when it was given in large, widely
spaced doses. Taking vitamin D supplements was found to be safe.
Conclusion
Taking a vitamin D supplement can protect against ARIs. The strongest effects are seen when a daily or
weekly supplement is given to people with the lowest vitamin D levels.
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Scientific summary
Background
Acute respiratory infections (ARIs) are a major cause of global morbidity and mortality. Observational
studies report consistent independent associations between low serum concentrations of 25-hydroxyvitamin
D [25(OH)D], the major circulating vitamin D metabolite, and susceptibility to ARI. The observation that
25(OH)D supports induction of antimicrobial peptides in response to both viral and bacterial stimuli suggests
a potential mechanism by which vitamin D-inducible protection against these outcomes may be mediated.
Vitamin D metabolites have also been reported to induce other innate antimicrobial effector mechanisms,
including autophagy and synthesis of reactive nitrogen intermediates and reactive oxygen intermediates.
These epidemiological and in vitro data have prompted numerous randomised controlled trials (RCTs) to
determine whether or not vitamin D supplementation can decrease the risk of ARI. A total of five aggregate
data meta-analyses incorporating data from up to 15 primary trials have been conducted to date, of which
two report statistically significant protective effects and three report no statistically significant effects. All but
one of these aggregate data meta-analyses reported significant heterogeneity of effect between primary trials.
Such heterogeneity of effect may have arisen as a result of intertrial variation in participant characteristics
and in dosing regimens, either of which may modify the effects of vitamin D supplementation on immunity
to respiratory pathogens. Subgroup analyses within primary trials of vitamin D supplementation for diverse
indications show that participants with lower baseline vitamin D status may derive greater clinical benefit
from supplementation than those with higher baseline status. Administration of large boluses of vitamin D
has been associated with reduced efficacy for non-classical effects of vitamin D and, in some cases, increased
risk of adverse outcomes. Although study-level factors are amenable to exploration via aggregate data
meta-analysis of published data, potential effect modifiers operating at an individual level, such as baseline
vitamin D status, can only be explored using individual participant data (IPD) meta-analysis. This is because
subgroups are not consistently disaggregated in trial reports, and consistent adjustments for potential
confounders cannot be applied. In order to determine the overall effect of vitamin D supplementation on the
risk of ARI and to identify factors that might modify the effects of this intervention on the risk of ARI, we
undertook a meta-analysis of IPD from RCTs that had investigated these outcomes.
Main objectives
1. To determine the overall effect of vitamin D supplementation on the risk of ARI and serious
adverse events.
2. To determine whether or not the following factors modify the effect of vitamin D supplementation on
the risk of ARI:
i. baseline vitamin D status
ii. vitamin D dosing regimen
iii. size of vitamin D dose
iv. age
v. body mass index
vi. presence versus absence of respiratory comorbidity [e.g. asthma, chronic obstructive pulmonary
disease (COPD)]
vii. influenza vaccination status.
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Methods
Data sources
Two investigators searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials
(CENTRAL), Web of Science, ClinicalTrials.gov and the International Standard Randomised Controlled Trials
Number (ISRCTN) registry for eligible studies from database inception until December 2015.
Study selection (eligibility criteria)
Randomised, double-blind, placebo-controlled trials of supplementation with vitamin D3 or vitamin D2 of
any duration were eligible for inclusion in the ARI analysis if they had been approved by a Research Ethics
Committee and if data on incidence of ARI were collected prospectively and prespecified as an efficacy
outcome. Studies reporting results of long-term follow-up of primary RCTs were excluded.
Data management
Individual participant data were requested from the principal investigator for each eligible trial, and the
terms of collaboration were specified in a data transfer agreement, signed by representatives of the data
provider and the recipient (Queen Mary University of London). Data relating to study characteristics were
extracted for the following variables: setting, eligibility criteria, details of intervention and control regimens,
study duration and case definitions for ARI. IPD were extracted for the following variables, when available:
baseline data were requested for age, sex, cluster identification (cluster randomised trials only), influenza
vaccination status, history of asthma, history of COPD, weight, height (adults and children able to stand) or
length (infants), serum 25(OH)D concentration, study allocation (vitamin D vs. placebo) and details of any
stratification or minimisation variables. Follow-up data were requested for the total number of ARIs, upper
respiratory infections (URIs) and lower respiratory infections (LRIs) experienced during the trial, time from
first dose of study medication to first ARI/URI/LRI if applicable, total number of courses of antibiotics taken
for ARI during the trial, total number of days off work or school as a result of ARI symptoms during the
trial, serum 25(OH)D concentration at final follow-up, duration of follow-up, number and nature of serious
adverse events, number of adverse reactions (incident hypercalcaemia or renal stones) and end-trial status
(completed vs. withdrew vs. lost to follow-up vs. died).
Data were de-identified at source prior to transfer via e-mail. On receipt, three investigators assessed data
integrity by performing internal consistency checks and by attempting to replicate the results of the
analysis for ARI incidence when this was published in the trial report. Study authors were contacted to
provide missing data and to resolve queries arising from these integrity checks. Once queries had been
resolved, clean data were uploaded to the main study database.
Assessment of validity
The Cochrane Collaboration Risk of Bias tool was used to assess the following variables: sequence generation;
allocation concealment; blinding of participants, personnel and outcome assessors; completeness of outcome
data; evidence of selective outcome reporting; and other potential threats to validity.
Data synthesis
Initially, all studies were reanalysed separately; the original authors were asked to confirm the accuracy of this
reanalysis when it had been performed previously, and any discrepancies were resolved. Then we performed
both one-step and two-step IPD meta-analysis using a random-effects model adjusted for age, sex and study
duration to obtain the pooled intervention effect on (1) the proportion of participants experiencing at least
one ARI, (2) ARI rate and (3) time to first ARI with a 95% confidence interval (CI). The number needed to treat
(NNT) for an additional beneficial outcome was calculated in which meta-analysis of dichotomous outcomes
revealed a statistically significant beneficial effect of allocation to vitamin D compared with placebo.
In order to explore the causes of heterogeneity and identify factors modifying the effects of vitamin D
supplementation on ARI risk, we also performed prespecified subgroup analyses by extending the one-step
meta-analysis framework to include treatment–covariate interaction terms. Subgroups were defined
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according to baseline vitamin D status [serum 25(OH)D concentration of < 25 nmol/l vs. ≥ 25 nmol/l],
vitamin D dosing regimen [daily or weekly administration without bolus dosing vs. administration of a
regimen including at least one bolus dose of ≥ 30,000 IU (international units) of vitamin D], dose size
(daily equivalent < 800 IU vs. 800–1999 IU vs. ≥ 2000 IU), age (≤ 1 year vs. 1.1–15.9 years vs. 16–65 years
vs. > 65 years), body mass index (< 25 kg/m2 vs. ≥ 25 kg/m2) and presence versus absence of asthma,
COPD and previous influenza vaccination. Interaction analyses were adjusted for potential confounders
(age, sex and study duration) in order to ensure that reported subgroup effects were independent. In order
to minimise the chance of type I error arising from multiple analyses, significance was inferred only when
p-values for treatment–covariate interaction terms were < 0.05.
Results
We identified 25 RCTs (total 11,321 participants, aged from 0 to 95 years) that were eligible for the ARI
analysis. These trials were conducted in 15 different countries on four continents and enrolled participants
of both sexes from birth to 95 years of age. The mean baseline 25(OH)D concentration ranged from 18.9
to 88.9 nmol/l. All studies administered oral vitamin D3 to participants in the intervention arm: this was
given as monthly to once every 3 months bolus doses in seven studies, as weekly doses in three studies, as
a daily dose in 12 studies and as a combination of bolus and daily doses in three studies. Study duration
ranged from 7 weeks to 1.5 years. Incidence of ARI was a primary or coprimary outcome for 14 studies
and a secondary outcome for 11 studies.
Individual participant data were obtained for 10,933 out of 11,321 (96.6%) participants in these studies.
In the one-step IPD meta-analysis, vitamin D supplementation resulted in a statistically significant reduction
in the proportion of participants experiencing at least one ARI [adjusted Odds Ratio (aOR) 0.88, 95% CI
0.81 to 0.96; p = 0.003, p for heterogeneity < 0.001; 10,933 participants in 25 studies]. The number
needed to benefit was 33 (95% CI 20 to 101). Statistically significant protective effects of vitamin D were
also seen for one-step analyses of ARI rate [adjusted incidence rate ratio (aIRR) 0.96, 95% CI 0.92 to 0.997;
p = 0.04; p for heterogeneity < 0.001; 10,703 participants in 25 studies] but not for analysis of time to first
ARI [adjusted hazard ratio (aHR) 0.95, 95% CI 0.89 to 1.01; p = 0.09; p for heterogeneity < 0.001; 9108
participants in 18 studies]. Two-step analyses showed consistent effects for the proportion of participants
experiencing at least one ARI (aOR 0.80, 95% CI 0.69 to 0.93; p = 0.004; p for heterogeneity = 0.001;
10,899 participants in 24 studies), ARI rate (aIRR 0.91, 95% CI 0.84 to 0.98; p = 0.018; p for heterogeneity
< 0.001; 10,703 participants in 25 studies) and time to first ARI (aHR 0.92, 95% CI 0.85 to 1.00; p = 0.051;
p for heterogeneity = 0.14; 9108 participants in 18 studies). Vitamin D did not influence the proportion of
participants experiencing at least one serious adverse event (aOR 0.98, 95% CI 0.80 to 1.20; p = 0.83).
This evidence was assessed as being of high quality.
Subgroup analyses revealed a strong protective effect of vitamin D supplementation among individuals
with baseline circulating 25(OH)D concentration of < 25 nmol/l (aOR 0.58, 95% CI 0.40 to 0.82; NNT 8,
95% CI 5 to 21; 538 participants in 14 studies; within subgroup, p = 0.002), and no statistically significant
effect among those with baseline 25(OH)D concentration of ≥ 25 nmol/l (aOR 0.89, 95% CI 0.77 to 1.04;
3634 participants in 19 studies; within subgroup, p = 0.15; for interaction, p = 0.01). Stronger protective
effects of vitamin D against ARIs were also seen in trials in which vitamin D was administered using a daily or
weekly regimen without additional bolus doses (aOR 0.81, 95% CI 0.72 to 0.91; NNT 20, 95% CI 13 to 43;
5133 participants in 15 studies; within subgroup, p < 0.001); no such protective effect was seen among
participants in trials in which at least one bolus dose of vitamin D was administered (aOR 0.97, 95% CI 0.86
to 1.10; 5800 participants in 10 studies; within subgroup, p = 0.67; p for interaction = 0.05). For both of
these subgroup analyses, broadly consistent effects were observed for event rate analysis and survival
analysis. The p-values for interaction were > 0.05 for all other potential effect modifiers investigated.
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We then proceeded to stratify the subgroup analyses according to dosing frequency, in order to provide a
cleaner look at results of subgroup analyses under the assumption that administration of bolus doses was
ineffective.The results of this exploratory analysis suggested that daily or weekly administration of vitamin D
induced an even greater degree of protection against ARI among participants with baseline circulating
25(OH)D concentrations of < 25 nmol/l than in the unstratified analysis (aOR 0.30, 95% CI 0.17 to 0.53;
NNT 4, 95% CI 3 to 7; 234 participants in six studies; within subgroup, p < 0.001). Moreover, administration
of daily or weekly vitamin D also protected against ARI among participants with higher baseline 25(OH)D
concentrations (aOR 0.75, 95% CI 0.60 to 0.95; NNT 15, 95% CI 9 to 86; 1603 participants in six studies;
within subgroup, p= 0.02). The p-value for interaction for this subgroup analysis was 0.006, indicating that
protective effects of daily or weekly vitamin D supplementation were significantly greater in the subgroup of
participants with profound vitamin D deficiency. No other statistically significant interaction was seen; notably,
bolus dose vitamin D supplementation did not offer any protection against ARI even when administered to
those with circulating 25(OH)D concentrations of < 25 nmol/l (aOR 0.82, 95% CI 0.51 to 1.33; 304 participants
in eight studies; within subgroup, p= 0.43).
Limitations
Our power to detect effects of vitamin D supplementation was limited for some subgroups [e.g. individuals
with baseline 25(OH)D concentration of < 25 nmol/l receiving bolus-dosing regimens]. Null and borderline
significant results for analyses of these outcomes may have arisen as a consequence of type II error. Data
relating to adherence to study medication were not available for all subjects. However, the inclusion of
non-adherent participants would bias results of our intention-to-treat analysis towards the null; thus, we
conclude that effects of vitamin D in those who are fully adherent to supplementation will be no less than
those reported for the study population overall. Finally, we caution that study definitions of ARI were diverse,
and virological, microbiological and/or radiological confirmation was obtained for a minority of events. ARI is
often a clinical diagnosis in practice, however, and as all studies were double-blind and placebo-controlled,
differences in incidence of events between study arms cannot be attributed to observation bias.
Conclusions
Implications for health care
Our synthesis of the current evidence suggests that vitamin D supplementation can prevent ARIs, broadly
defined. We identified that the greatest potential benefit is for those individuals who are very deficient in
vitamin D. Those receiving daily or weekly supplementation without additional bolus doses also experienced
particular benefit. Our results add to the body of evidence supporting the introduction of public health
measures, such as food fortification, to improve vitamin D status in settings in which profound vitamin D
deficiency is common.
Recommendations for research
1. Incorporation of additional IPD from ongoing trials in the field has the potential to increase statistical
power for subgroup analyses; this IPD meta-analysis should therefore be updated when a significant
new body of data has accumulated.
2. Given the major impact of ARIs on economic productivity and health-care use, our findings are likely to
influence the economic case for the introduction of vitamin D fortification of foods in the UK. Economic
models of the cost-effectiveness of vitamin D fortification in the UK should therefore be updated to
take account of the previously unappreciated protective effects of vitamin D against ARIs.
SCIENTIFIC SUMMARY
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Study registration
This study is registered as PROSPERO CRD42014013953.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Acute respiratory infections (ARIs) are a major cause of global morbidity and mortality, responsible for10% of ambulatory and emergency department visits in the USA1 and an estimated 2.65 million
deaths worldwide in 2013.2 Viral ARI precipitate the majority of acute exacerbations of asthma and chronic
obstructive pulmonary disease (COPD),3 which represent the major cause of morbidity and mortality in
people with these conditions.4,5
Observational studies report consistent independent associations between low serum concentrations of
25-hydroxyvitamin D [25(OH)D], the major circulating vitamin D metabolite, and susceptibility to ARI6,7 and
acute exacerbations of asthma;8,9 such observational studies have yielded more conflicting results for the
outcomes of COPD exacerbation.10–12 The observation that 25(OH)D supports induction of antimicrobial
peptides in response to both viral and bacterial stimuli13–15 suggests a potential mechanism by which
vitamin D-inducible protection against these outcomes may be mediated. Vitamin D metabolites have
also been reported to induce other innate antimicrobial effector mechanisms, including autophagy and
synthesis of reactive nitrogen intermediates and reactive oxygen intermediates.16 In addition, vitamin D
metabolites have been reported to induce anti-inflammatory activity via multiple mechanisms, including
induction of the regulatory cytokine interleukin (IL) 1017 and inhibition of the pro-inflammatory cytokine
IL-17A.18 We have also recently shown that 25(OH)D attenuates rhinovirus-induced expression of the genes
encoding intercellular adhesion molecule 1 (ICAM-1, a cell surface glycoprotein that acts as the cellular
receptor for major group rhinoviruses) and platelet-activating factor receptor (PAFR, a G-protein coupled
receptor implicated in adhesion of Streptococcus pneumoniae to respiratory epithelial cells).19 These
findings suggest possible mechanisms by which vitamin D may enhance resistance to rhinovirus infection
and reduce risk of secondary bacterial infection in vitamin D-deficient individuals.
These epidemiological and in vitro data have prompted numerous randomised controlled trials (RCTs) to
determine whether or not vitamin D supplementation can decrease the risk of ARI and acute exacerbations
of asthma and COPD. For the outcome of ARI, a total of five aggregate data meta-analyses incorporating
data from up to 15 primary trials have been conducted to date, of which two report statistically significant
protective effects20,21 and three report no statistically significant effects.22–24 All but one of these aggregate
data meta-analyses22 reported significant heterogeneity of effect between primary trials. For the outcome
of asthma exacerbation, a total of four aggregate data meta-analyses incorporating data from up to
nine primary trials have been conducted to date, of which three report statistically significant protective
effects23,25,26 and one reports no statistically significant effects.27 The most recent of these – and the one
incorporating data from the most studies – reported a high degree of heterogeneity of effect between
trials for the outcome of study-defined asthma exacerbation.26 We are not aware of any published
meta-analyses investigating effects of vitamin D supplementation on the risk of COPD exacerbation,
which may reflect the fact that only three primary trials investigating this question have been published
to date.28–30
When heterogeneity of effect is present, it may have arisen as a result of intertrial variation in participant
characteristics and in dosing regimens, either of which may modify the effects of vitamin D supplementation
on immunity to respiratory pathogens.31 Subgroup analyses within primary trials suggest that COPD patients
with lower baseline vitamin D status may derive greater clinical benefit from supplementation than those
with higher baseline status.28,29 Moreover, participant characteristics such as age and body mass index have
been reported to modify the 25(OH)D response to vitamin D supplementation.32,33 Administration of large
boluses of vitamin D has been associated with reduced efficacy for non-classical effects20 and, in some
cases, increased risk of adverse outcomes.34 Although study-level factors are amenable to exploration via
aggregate data meta-analysis of published data, potential effect modifiers operating at an individual level,
such as baseline vitamin D status, can only be explored using individual participant data (IPD) meta-analysis.
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This is because subgroups are not consistently disaggregated in trial reports, and consistent adjustments
for potential confounders cannot be applied.35 In order to identify factors that might modify effects of
vitamin D supplementation on the risk of ARI and acute exacerbations of asthma and COPD, we undertook
a meta-analysis of IPD from RCTs that had investigated these outcomes. The results of some of these
analyses have been published elsewhere.36–38
BACKGROUND
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Chapter 2 Research questions
1. What is the overall effect of vitamin D supplementation on the risk of:
i. acute respiratory infections, incorporating events classified as upper respiratory infections (URIs),
lower respiratory infections (LRIs) and ARIs of unclassified location (i.e. infection of the upper and/or
lower respiratory tract)
ii. upper respiratory infections and LRIs, analysed separately
iii. emergency department attendance and/or hospital admission for ARI
iv. use of antimicrobials for treatment of ARI
v. work/school absence as a result of ARI
vi. severe exacerbations of asthma
vii. severe exacerbations of COPD
viii. serious adverse events
ix. potential adverse reactions to vitamin D (hypercalcaemia and renal stones)
x. mortality (related to ARI/respiratory failure, infection and all-cause) and to identify factors modifying
this effect?
2. Do the following factors modify the effect of vitamin D supplementation on the risk of ARI?
i. baseline vitamin D status [serum 25(OH)D concentration of < 25 nmol/l vs. ≥ 25 nmol/l]
ii. dosing regimen [daily or weekly administration of vitamin D without bolus dosing vs. administration
of a regimen including at least one bolus dose of ≥ 30,000 international units (IU) of vitamin D]
iii. dose size (daily equivalent < 800 IU vs. 800–1999 IU vs. ≥ 2000 IU of vitamin D)
iv. age (≤ 1 year vs. 1.1–15.9 years vs. 16–65 years vs. > 65 years)
v. body mass index (< 25 kg/m2 vs. ≥ 25 kg/m2)
vi. presence versus absence of respiratory comorbidity (asthma, COPD)
vii. influenza vaccination status.
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Chapter 3 Methods
Protocol and registration
Methods were prespecified in a protocol that was registered with the PROSPERO International Prospective
Register of Systematic Reviews [www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014013953
accessed 1 May 2018]. Research Ethics Committee approval to conduct this meta-analysis was not required
in the UK; local ethics permission to contribute de-identified IPD from primary trials was required and
obtained for studies by Camargo et al.39 (the Ethics Review Committee of the Mongolian Ministry of Health),
Murdoch et al.40 (Southern Health and Disability Ethics Committee, reference URB/09/10/050/AM02), Rees
et al.41 (Committee for the Protection of Human Subjects, Dartmouth College, NH, USA; Protocol no 24381),
Tachimoto et al.42 (Ethics Committee of the Jikei University School of Medicine, reference 26-333: 7839),
Tran et al.43 (QIMR Berghofer Medical Research Institute Human Research Ethics Committee, reference
number P1570) and Urashima et al.44,45 (Ethics Committee of the Jikei University School of Medicine,
reference 26-333: 7839).
Patient and public involvement
Two patient and public involvement (PPI) representatives were involved in development of the research
question and the choice of outcome measures specified in the study protocol through discussion with the
investigators. When possible, results of this systematic review and meta-analysis will be disseminated to
individual participants via the principal investigators of each trial (e.g. via e-mail to participants who have
requested updates on how their data are being used). PPI representatives and participants in primary trials
are thanked for their contributions in the Acknowledgements.
Eligibility criteria
For the IPD meta-analysis of ARI outcomes, randomised, double-blind, placebo-controlled trials of
supplementation with vitamin D3 or vitamin D2 of any duration were eligible for inclusion if they had been
approved by a Research Ethics Committee and if data on incidence of ARI were collected prospectively and
prespecified as an efficacy outcome. The last requirement was imposed to minimise misclassification bias
(prospectively designed instruments to capture these events were deemed more likely to be sensitive and
specific for this outcome). Studies reporting results of long-term follow-up of primary RCTs were excluded.
For the IPD meta-analysis of asthma exacerbation, randomised, double-blind, placebo-controlled trials of
supplementation with vitamin D3 or vitamin D2 in patients with asthma were eligible for inclusion if they
had been approved by a Research Ethics Committee and if data on incidence of asthma exacerbation
were reported.
For the IPD meta-analysis of COPD exacerbation, randomised, double-blind, placebo-controlled trials of
supplementation with vitamin D3 or vitamin D2 in patients with COPD were eligible for inclusion if they
had been approved by a Research Ethics Committee and if data on incidence of COPD exacerbation
were reported.
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Study identification and selection
Two investigators (ARM and DAJ) searched MEDLINE, EMBASE, the Cochrane Central Register of
Controlled Trials (CENTRAL), Web of Science, ClinicalTrials.gov and the International Standard Randomised
Controlled Trials Number (ISRCTN) registry using the electronic search strategies described in Appendix 1.
Searches were regularly updated up to and including 31 December 2015 for the ARI analysis, 26 October
2016 for the analysis of asthma exacerbations and 31 July 2017 for the analysis of COPD exacerbations.
No language restrictions were imposed. These searches were supplemented by searching review articles
and reference lists of trial publications. Collaborators were asked if they knew of any additional trials.
Three investigators (ARM, CAC and DAJ) determined which trials met the eligibility criteria; disagreements
were resolved by consensus. References were managed in EndNote X5 [Clarivate Analytics (formerly
Thomson Reuters), Philadelphia, PA, USA].
Data collection processes
Individual participant data were requested from the principal investigator for each eligible trial and the
terms of collaboration were specified in a data transfer agreement, signed by representatives of the data
provider and the recipient (Queen Mary University of London). Data were de-identified at source prior to
transfer via e-mail. On receipt, three investigators (DAJ, RLH and LG) assessed data integrity by performing
internal consistency checks and by attempting to replicate results of analyses that were published in trial
reports. Study authors were contacted to provide missing data and to resolve queries arising from these
integrity checks. Once queries had been resolved, clean data were uploaded to the main study database,
which was held in Stata® IC version12 (StataCorp LP, College Station, TX, USA).
Data relating to study characteristics were extracted for the following variables: setting, eligibility criteria,
details of intervention and control regimens, study duration and case definitions for ARI. IPD were extracted
for the following variables, when available: baseline data were requested for age, sex, cluster ID (cluster
randomised trials only), racial/ethnic origin, influenza vaccination status, history of asthma, history of COPD,
weight, height (adults and children able to stand) or length (infants), serum 25(OH)D concentration, study
allocation (vitamin D vs. placebo) and details of any stratification or minimisation variables. For all trials,
follow-up data were requested for serum 25(OH)D concentration at final follow-up, duration of follow-up,
number and nature of serious adverse events, number of adverse reactions (incident hypercalcaemia or renal
stones) and end-trial status (completed vs. withdrew vs. lost to follow-up vs. died). For trials contributing
IPD to the ARI analysis, follow-up data were also requested for the total number of ARIs, URIs and LRIs
experienced during the trial, time from first dose of study medication to first ARI/URI/LRI if applicable,
total number of courses of antibiotics taken for ARI during the trial and total number of days off work or
school as a result of ARI symptoms during the trial. For trials contributing IPD to the analysis of severe
asthma exacerbation, follow-up data were also requested for the total number of asthma exacerbations
experienced during the trial that were treated with systemic corticosteroids and the time from the first dose
of study medication to the first such exacerbation, if applicable. For trials contributing IPD to the analysis of
severe COPD exacerbation, follow-up data were also requested for the total number of COPD exacerbations
experienced during the trial that were treated with systemic corticosteroids and/or antibiotics and the time
from the first dose of study medication to the first such exacerbation if applicable.
Risk-of-bias assessment for individual studies
We used the Cochrane Collaboration Risk of Bias tool46 to assess the following variables: sequence generation;
allocation concealment; blinding of participants, personnel and outcome assessors; completeness of outcome
data; evidence of selective outcome reporting; and other potential threats to validity. Study quality was assessed
independently by two investigators (ARM and DAJ), except for the three trials by Martineau et al.,29,47,48 which
were assessed by Carlos A Camargo Jr. Discrepancies were resolved by consensus.
METHODS
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Definition of outcomes
The primary outcome of the meta-analysis was incidence of ARI, incorporating events classified as URIs,
LRIs and ARIs of unclassified location (i.e. infection of the upper and/or lower respiratory tract). Secondary
outcomes were incidence of URI and LRI, analysed separately; incidence of emergency department attendance
and/or hospital admission for ARI; use of antimicrobials for treatment of ARI; work/school absence as a result
of ARI; incidence of severe asthma exacerbation, defined as a worsening of asthma symptoms resulting in
treatment with systemic corticosteroids; incidence of severe COPD exacerbation, defined as a worsening of
symptoms resulting in treatment with systemic corticosteroids and/or antibiotics; incidence and nature of
serious adverse events; incidence of potential adverse reactions to vitamin D (hypercalcaemia and renal
stones); and mortality (related to ARI/respiratory failure, infection and all-cause).
Synthesis methods
Data were analysed by Lauren Greenberg and Richard L Hooper. Our IPD meta-analysis approach followed
published guidelines.35 Initially, all studies were reanalysed separately; the original authors were asked to
confirm the accuracy of this reanalysis when it had been performed previously, and any discrepancies were
resolved. We then performed both one-step and two-step IPD meta-analysis using a random-effects model
adjusted for age, sex and study duration to obtain the pooled intervention effect with a 95% confidence
interval (CI). We did not adjust for other covariates because missing values for some participants would
have led to their exclusion from statistical analyses. In the one-step approach, IPD from all studies were
modelled simultaneously while accounting for the clustering of participants within studies. In the two-step
approach, IPD were first analysed for each separate study independently to produce an estimate of the
treatment effect for that study; these data were then synthesised in a second step.35 For one-step IPD
meta-analysis, heterogeneity was assessed by calculation of the standard deviation of random effects;
for two-step IPD meta-analysis, heterogeneity was summarised using the I2 statistic. The number needed
to treat (NNT) for an additional beneficial outcome was calculated using the Visual Rx NNT calculator
(www.nntonline.net/visualrx/) when meta-analysis of dichotomous outcomes revealed a statistically
significant beneficial effect of allocation to vitamin D versus placebo.
Exploration of variation in effects
In order to explore the causes of heterogeneity and identify factors modifying the effects of vitamin D
supplementation on ARI risk, we performed prespecified subgroup analyses by extending the one-step
meta-analysis framework to include treatment–covariate interaction terms. Subgroups were defined
according to baseline vitamin D status [serum 25(OH)D concentration of < 25 nmol/l vs. ≥ 25 nmol/l],
vitamin D dosing regimen (daily or weekly administration without bolus dosing vs. administration of a
regimen including at least one bolus dose of ≥ 30,000 IU of vitamin D), dose size (daily equivalent
< 800 IU vs. 800–1999 IU vs. ≥ 2000 IU), age (≤ 1 year vs. 1.1–15.9 years vs. 16–65 years vs. > 65 years),
body mass index (< 25 kg/m2 vs. ≥ 25 kg/m2), presence versus absence of asthma or COPD and previous
influenza vaccination status. Interaction analyses were adjusted for potential confounders (age, sex and
study duration) to ensure that reported subgroup effects were independent. The 25 nmol/l cut-off point for
baseline 25(OH)D concentration in subgroup analyses was selected on the basis that it is the threshold for
vitamin D deficiency defined by the UK Department of Health and Social Care49 and the level below which
participants in clinical trials have experienced the most consistent benefits of supplementation.50 In order
to minimise the chance of type I error arising from multiple analyses, significance was inferred only when
p-values for treatment–covariate interaction terms were < 0.05.
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Quality assessment across studies
For the primary analysis, the likelihood of publication bias was investigated through the construction of a
contour-enhanced funnel plot.51 We used the five Grading of Recommendations Assessment, Development
and Evaluation (GRADE) considerations [(1) (study limitations, (2) consistency of effect, (3) imprecision,
(4) indirectness and (5) publication bias]52 to assess the quality of the body of evidence contributing to
analyses of the primary efficacy outcome and major safety outcome of our meta-analysis.
Additional analyses
For the ARI analysis, we conducted sensitivity analyses excluding IPD from trials in which ARI was a
secondary outcome (as opposed to a primary or coprimary outcome) and in which risk of bias was assessed
as being unclear. We also conducted a responder analysis in participants randomised to the intervention
arm of included studies for whom end-study 25(OH)D concentration data were available, comparing risk of
ARI in those who attained a serum concentration of 25(OH)D of ≥ 75 nmol/l with that in those who did not.
METHODS
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Chapter 4 Results
Study selection and individual participant data obtained
For the ARI analysis, our search identified a total of 532 unique studies that were assessed for eligibility; of
these, 25 studies with a total of 11,321 randomised participants fulfilled eligibility criteria. IPD were sought
and obtained for all 25 studies. Outcome data were obtained for 10,933 out of 11,321 (96.6%) of the
randomised participants in these 25 studies (Figure 1).
For the analysis of severe asthma exacerbations, our search identified a total of 483 unique studies that
were assessed for eligibility; of these, eight studies with a total of 1078 randomised participants fulfilled
eligibility criteria. IPD were obtained for seven of the eight studies. Outcome data were obtained for 955
out of 978 (97.6%) of the randomised participants in these seven studies (Figure 2).
For the analysis of severe COPD exacerbations, our search identified a total of 254 unique studies that
were assessed for eligibility; of these, three studies with a total of 510 randomised participants fulfilled
eligibility criteria. IPD were obtained for two of the three studies. Outcome data were obtained for 422 out
of 422 (100%) of the randomised participants in these two studies (Figure 3).
Additional studies identified
through other sources, including
contact with researchers
(n = 3)
Studies ineligible
(not relevant, review article, not
RCTs, ARI not prespecified as
efficacy outcome)
(n = 507)
Unique studies after duplicates removed
(n = 532)
Studies identified through database searching
(n = 717)
Studies with total of 11,321 randomised
participants eligible; IPD sought for all
(n = 25)
Available data
• IPD obtained for 25/25 eligible studies
• Randomised participants with outcome data
   for primary analysis, n = 10,933
• Randomised participants with missing 
   outcome data for primary analysis, n = 388
• MEDLINE, n = 261
• CENTRAL, n = 146
• EMBASE, n = 52
• Web of Science, n = 258
FIGURE 1 The PRISMA flow diagram: ARI analysis. CENTRAL, Cochrane Central Register of Controlled Trials;
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
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Excluded
(n = 475)
IPD not obtained for 1 eligible
study (100 participants)
Unique studies after duplicates removed
(n = 483)
Studies identified through database searching
(n = 776)
Studies with total of 1078 randomised
participants eligible; IPD sought for all
(n = 8)
Available data
• IPD obtained for 7/8 eligible studies 
   (978 randomised participants)
• Proportion of randomised participants with
   outcome data available for analysis: 955/978
   (97.6%)
• Not relevant, n = 374
• Review article, n = 45
• Not double-blind randomised
   placebo-controlled trial, n = 34
• Data on asthma exacerbation
   not reported, n = 22
• MEDLINE, n = 270
• CENTRAL, n = 165
• EMBASE, n = 106
• Web of Science, n = 235
FIGURE 2 The PRISMA flow diagram: asthma exacerbation analysis. CENTRAL, Cochrane Central Register of
Controlled Trials; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
Excluded
(n = 183)
IPD not obtained for 1 eligible
study (88 participants)
Unique studies after duplicates removed
(n = 186)
Studies identified through database searching
(n = 254)
Studies with total of 510 randomised
participants eligible; IPD sought for all
(n = 3)
Available data
• IPD obtained for 2/3 eligible studies 
   (422 randomised participants)
• Randomised participants with outcome 
   data, n = 422
• Not relevant, n = 107
• Review article, n = 42
• Not double-blind randomised
   placebo-controlled trial, n = 30
• Data on acute COPD
   exacerbation not reported, n = 4
• PubMed, n = 108
• CENTRAL, n = 62
• EMBASE, n = 3
• Web of Science, n = 81
FIGURE 3 The PRISMA flow diagram: COPD exacerbation analysis. CENTRAL, Cochrane Central Register of
Controlled Trials; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
RESULTS
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Study and participant characteristics
Characteristics of studies contributing data to this meta-analysis and their participants are presented in
Table 1.
Trials were conducted in 15 different countries on four continents and enrolled participants of both sexes
from birth to 95 years of age. Baseline serum 25(OH)D concentrations were determined in 21 out of
27 trials: the mean baseline 25(OH)D concentration ranged from 18.9 to 88.9 nmol/l. All studies administered
oral vitamin D3 to participants in the intervention arm: this was given as monthly to once every 3 months
bolus doses in seven studies, as weekly doses in three studies, as a daily dose in 13 studies, and as a
combination of bolus and daily doses in four studies. Study duration ranged from 7 weeks to 1.5 years.
Incidence of ARI was a primary or coprimary outcome for 14 studies, and a secondary outcome for
11 studies. Incidence of asthma exacerbation was a primary or coprimary outcome for two studies and a
secondary outcome for five studies. Incidence of COPD exacerbation was a primary or coprimary outcome
for two studies; no study included this as a secondary outcome.
The integrity of the IPD was confirmed by replication of the primary analyses in published papers when
applicable. The process of checking IPD identified three minor errors in published reports. For the 2012
trial by Manaseki-Holland et al.,58 the correct number of repeat episodes of chest radiograph-confirmed
pneumonia was 134, rather than 138 as reported. For the trial by Dubnov-Raz et al.,64 the number of
patients randomised to the intervention arm was 27, rather than 28 as reported. For the trial by Laaksi
et al.,55 the proportion of men randomised to placebo who did not experience any ARI was 30 out of 84,
rather than 30 out of 80 as reported.
Risk of bias within studies
Details of the risk-of-bias assessment are provided in Table 2.
All but three trials were assessed as being at a low risk of bias for all aspects assessed. Three trials
were assessed as being at an unclear risk of bias owing to high rates of loss to follow-up. In the trial by
Dubnov-Raz et al.,64 52% of participants did not complete all symptom questionnaires. In the trial by
Laaksi et al.,55 37% of randomised participants were lost to follow-up. In the trial by Kerley et al.,67
24% of randomised participants were lost to follow-up.
Overall results: acute respiratory infection incidence
The results of the one-step IPD meta-analysis testing the effects of vitamin D on the proportion of all participants
experiencing at least one ARI, adjusting for age, sex and study duration, are presented in Table 3. Vitamin D
supplementation resulted in a statistically significant reduction in the proportion of participants experiencing at
least one ARI [adjusted odds ratio (aOR) 0.88, 95% CI 0.81 to 0.96, p= 0.003; p for heterogeneity < 0.001;
NNT 33, 95% CI 20 to 101; 10,933 participants in 25 studies; Cates plot, Figure 4].
Statistically significant protective effects of vitamin D were also seen for the one-step analyses of ARI rate
[adjusted incidence rate ratio (aIRR) 0.96, 95% CI 0.92 to 0.997; p = 0.04 and p for heterogeneity < 0.001]
in 10,703 participants in 25 studies (Table 4). However, the protective effects of vitamin D were not seen
in the analysis of time to first ARI [adjusted hazard ratio (aHR) 0.95, 95% CI 0.89 to 1.01; p = 0.09 and
p for heterogeneity < 0.001] in 9108 participants in 18 studies (Table 5). Two-step analyses also showed
consistent effects for the proportion of participants experiencing at least one ARI (aOR 0.80, 95% CI 0.69
to 0.93; p = 0.004 and p for heterogeneity = 0.001) in 10,899 participants in 24 studies (Figure 5), ARI rate
(aIRR 0.91, 95% CI 0.84 to 0.98; p = 0.018 and p for heterogeneity < 0.001) in 10,703 participants in
25 studies, and time to first ARI (aHR 0.92, 95% CI 0.85 to 1.00; p = 0.051 and p for heterogeneity = 0.14)
in 9108 participants in 18 studies. This evidence was assessed as being of high quality.
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TABLE 1 Characteristics of the trials contributing data to analyses, and their participants
First
author
and year Setting Participants
Mean age
(years) (SD)
[range] Male : female
25(OH)D assay,
EQA scheme
Mean baseline
25(OH)D
concentration
(nmol/l) (SD)
[range]
Baseline
25(OH)D
concentration
< 25nmol/l
(%)
Intervention :
control
Oral dose of
vitamin D3,
intervention
arm Control
Study
duration Outcome ARI definition
n entering
analysis/N
randomised
(%)
Li-Ng
2009
53
USA Healthy adults 57.9 (13.6)
[21.4–80.6]
34 : 128 RIA (DiaSorin,
Saluggia, Italy)
63.7 (25.5)
[16.0–156.0]
3/150 (2.0) 84 : 78 50 µg daily Placebo 3 months ARI (1y) URI: ≥ 2 URI
symptoms in
absence of
allergy symptoms
157/162 (96.9)
Urashima
2010
45
Japan Schoolchildren 10.2 (2.3)
[6.0–15.0)
242 : 188 – Not determined – 217 : 213 30 µg daily Placebo 4 months ARI (1y),
asthma
exacerbation.
(2y in subset)
URI: influenza A/B
diagnosed by
RIDT or RIDT-
negative ILI
334/430 (77.7),
ARI; 99/110,
asthma
exacerbation
Manaseki-
Holland
2010
54
Afghanistan Pre-school
children with
pneumonia
1.1 (0.8)
[0.1–3.3]
257 : 196 – Not determined – 224 : 229 2.5-mg bolus,
once
Placebo 3 months ARI (2y) LRI: repeat
episode of
pneumonia –
age-specific
tachypnoea
without wheeze
453/453 (100.0)
Laaksi
2010
55
Finland Military
conscripts
19.1 (0.6)
[18.0–21.0]
164 : 0 EIA
[Immunodiagnostic
Systems Holdings
plc (IDS), The
Boldons, UK;
Octeia®]
75.9 (18.7)
[41.9–129.0]
0/73 (0.0) 80 : 84 10 µg daily Placebo 6 months ARI (1y) ARI: medical
record diagnosis
164/164 (100.0)
Majak
2011
56
Poland Children with
asthma
10.9 (3.3)
[6.0–17.0]
32 : 16 RIA (BioSource
Europe, S.A.,
Nivelles, Belgium)
88.9 (38.2)
[31.5–184.7]
0/48 (0.0) 24 : 24 12.5 µg daily Placebo 6 months Asthma
exacerbation
(1y), ARI (2y)
ARI: self-report 48/48 (100.0),
asthma
exacerbation and
ARI
Trilok
Kumar
2011
57
India Low-
birthweight
infants
0.1 (0.0)
[0.0–0.3]
970 : 1109 – Not determined Not
determined
1039 : 1040 35 µg weekly Placebo 6 months ARI (2y) ARI: medical
record diagnosis
of events causing
hospitalisation
2064/2079
(99.3)
Lehouck
2012
28
Belgium Adults with
COPD
67.9 (8.3)
[48.0–86.0]
145 : 37 RIA (DiaSorin) 49.8 (29.2)
[9.0–159.7]
31/182 (17.0) 91 : 91 2.5-mg bolus
monthly
Placebo 1 year COPD
exacerbation
(1y), ARI (2y)
URI: self-report 175/182 (96.2),
ARI; 180/182
COPD
exacerbation
Manaseki-
Holland
2012
58
Afghanistan Infants 0.5 (0.3)
[0.0–1.0]
1591 : 1455 – Not determined Not
determined
1524 : 1522 2.5-mg bolus
once every
3 months
Placebo 1.5 years ARI (1y) LRI: pneumonia
confirmed by
chest radiograph
3011/3046
(98.9)
Camargo
2012
39
Mongolia Third/fourth
grade
schoolchildren
10.0 (0.9)
[7.0–12.7]
129 : 118 LC-MS/MS 18.9 (9.7)
[3.3–61.2]
192/245 (78.4) 143 : 104 7.5 µg daily Placebo 7 weeks ARI (2y) ARI: parent-
reported ‘chest
infections or
colds’
244/247 (98.8)
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First
author
and year Setting Participants
Mean age
(years) (SD)
[range] Male : female
25(OH)D assay,
EQA scheme
Mean baseline
25(OH)D
concentration
(nmol/l) (SD)
[range]
Baseline
25(OH)D
concentration
< 25nmol/l
(%)
Intervention :
control
Oral dose of
vitamin D3,
intervention
arm Control
Study
duration Outcome ARI definition
n entering
analysis/N
randomised
(%)
Murdoch
2012
40
New
Zealand
Healthy adults 48.1 (9.7)
[18.0–67.6]
81 : 241 LC-MS/MS 72.1 (22.1)
[13.0–142.0]
5/322 (1.6) 161 : 161 2 × 5-mg bolus
monthly, then
2.5-mg bolus
monthly
Placebo 1.5 years ARI (1y) URI: assessed
with symptom
score
322/322 (100.0)
Bergman
2012
59
Sweden Adults with
increased
susceptibility to
ARI
53.1 (13.1)
[20.0–77.0]
38 : 102 CLA (DiaSorin) 49.3 (23.2)
[8.0–135.0]
15/131 (11.45) 70 : 70 100 µg daily Placebo 1 year ARI (2y) URI: assessed
with symptom
score
124/140 (88.6)
Marchisio
2013
60
Italy Children with
recurrent acute
otitis media
2.8 (1.0)
[1.3–4.8]
64 : 52 CLA (DiaSorin) 65.3 (17.3)
[24.7–120.6]
2/116 (1.7) 58 : 58 25 µg daily Placebo 6 months ARI (1y) URI: doctor-
diagnosed acute
otitis media
116/116 (100.0)
Rees
2013
41
USA Adults with
previous
colorectal
adenoma
61.2 (6.6)
[47.1–77.9]
438 : 321
a
RIA (IDS) 62.5 (21.3)
[30.2–171.6]
0/759 (0.0) 399 : 360 25 µg daily Placebo 13 months
(average)
ARI (2y) URI: assessed
from daily
symptom diary
759/759 (100.0)
Tran
2014
43
Australia Healthy older
adults
71.7 (6.9)
[60.3–85.2]
343 : 301 CLA (DiaSorin) 41.7 (13.5)
[12.6–105.0]
66/643 (10.3) 430 : 214 0.75-mg bolus
vs. 1.5-mg
bolus monthly
Placebo 1 year ARI (2y) URI: self-reported
cold
594/644 (92.2)
Goodall
2014
61
Canada Healthy
university
students
19.6 (2.2)
[17.0–33.0]
218 : 382 – Not determined – 300 : 300 0.25mg weekly
(factorial with
gargling)
Placebo 8 weeks ARI (1y) URI: self-reported
cold
492/600 (82.0)
Urashima
2014
44
Japan High school
students
16.5 (1.0)
[15.0–18.0]
162 : 85 – Not determined – 148 : 99 50 µg daily Placebo 2 months ARI (1y) URI: influenza A
diagnosed by
RIDT or RIDT-
negative ILI
247/247 (100.0)
Grant
2015
62
New
Zealand
Pregnant
women and
offspring
unborn 0 : 260
(mothers)
121 : 128
(offspring)
LC-MS/MS 54.8 (25.8)
[8.0–128.0]
30/200 (15.0) 173 : 87
(mothers)
164 : 85
(offspring)
Mothers: 25 µg
vs. 50 µg daily;
infants: 10 µg
vs. 20 µg daily
Placebo 9 months
(3 months in
pregnancy
and 6 months
in infancy)
ARI (2y) ARI: doctor-
diagnosed ARI
precipitating
primary care
consultation
236/260 (90.8)
Martineau
2015
29
(ViDiCO)
UK Adults with
COPD
64.7 (8.5)
[40.0–85.0]
144 : 96 LC-MS/MS 46.1 (25.7)
[0.0–160.0]
50/240 (20.8) 122 : 118 3-mg bolus
once every
2 months
Placebo 1 year ARI and
COPD
exacerbation
(Co1y)
URI: assessed
from daily
symptom diary
240/240 (100.0),
ARI and COPD
exacerbation
Martineau
2015
47
(ViDiAs)
UK Adults with
asthma
47.9 (14.4)
[16.0–78.0]
109 : 141 LC-MS/MS 49.6 (24.7)
[0.0–139.0]
36/250 (14.4) 125 : 125 3-mg bolus
once every
2 months
Placebo 1 year ARI and
asthma
exacerbation
(Co1y)
URI: assessed
from daily
symptom diary
250/250 (100.0),
ARI and asthma
exacerbation
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TABLE 1 Characteristics of the trials contributing data to analyses, and their participants (continued )
First
author
and year Setting Participants
Mean age
(years) (SD)
[range] Male : female
25(OH)D assay,
EQA scheme
Mean baseline
25(OH)D
concentration
(nmol/l) (SD)
[range]
Baseline
25(OH)D
concentration
< 25nmol/l
(%)
Intervention :
control
Oral dose of
vitamin D3,
intervention
arm Control
Study
duration Outcome ARI definition
n entering
analysis/N
randomised
(%)
Martineau
2015
48
(ViDiFlu)
UK Older adults
and their carers
67.1 (13.0)
[21.4–94.0]
82 : 158 LC-MS/MS 42.9 (23.0)
[0.0–128.0]
60/240 (25.0) 137 : 103 Older adults:
2.4-mg bolus
once every
2 months+
10 µg daily
Carers: 3mg
once every
2 months
Older adults:
placebo+10µg
daily
Carers: placebo
1 year ARI (1y) URI and LRI,
both assessed
from daily
symptom diary
240/240 (100.0)
Simpson
2015
63
Australia Healthy adults 32.2 (12.2)
[18.0–52.0]
14 : 20 LC-MS/MS 67.9 (23.0)
[32.0–132.0]
0/33 (0.0) 18 : 16 0.5mg weekly Placebo 17 weeks ARI (1y) ARI assessed
with symptom
score
34/34 (100.0)
Dubnov-
Raz 2015
64
Israel Adolescent
swimmers with
vitamin D
insufficiency
15.2 (1.6)
[12.9–18.6]
34 : 20 RIA (DiaSorin) 60.4 (11.9)
[28.0–74.6]
0/54 (0.0) 27 : 27 50 µg daily Placebo 12 weeks ARI (1y) URI assessed
with symptom
score
25/54 (46.3)
Castro
2014
65
/
Denlinger
2016
66
USA Adults with
asthma
39.2 (12.9)
[18.0–85.0]
130 : 278 CLA (DiaSorin) 47.0 (16.9)
[10.0–74.6]
55/408 (13.5) 201 : 207 2.5-mg bolus
then 100 µg
daily
Placebo 28 weeks Asthma
exacerbation
(2y), ARI (2y)
URI assessed
with symptom
score
408/408 (100.0),
ARI and asthma
exacerbation
Tachimoto
2016
42
Japan Children with
asthma
9.9 (2.3)
[6.0–15.0]
50 : 39 RIA (DiaSorin) 74.9 (24.6)
[20.0–187.2]
1/89 (1.1) 54 : 35 20 µg daily, first
2 months
Placebo 6 months Asthma
exacerbation
(2y), ARI (2y)
URI: assessed
with symptom
score
89/89 (100.0),
ARI and asthma
exacerbation
Kerley
2016
67
Ireland School children
with asthma
8.6 (2.8)
[5.0–15.0]
24 : 15 LC-MS/MS 54.4 (17.4)
[26–92]
0/39 (0.0) 17 : 22 50 µg daily Placebo 15 weeks Asthma
exacerbation
(2y)
n/a 39/51 (76.5)
Jensen
2016
68
Canada Preschool
children with
asthma
2.9 (1.1)
[1.6–5.5)
7 : 15 LC-MS/MS 64.2 (14.0) 0/22 (0.0) 11 : 11 2.5-mg bolus
then 10 µg daily
10 µg daily 6 months Asthma
exacerbation
(2y)
n/a 22/22 (100.0)
Ginde
2017
69
USA Institutionalised
older adults
80.7 (9.9)
[60.0–95.0]
45 : 62 LC-MS/MS 57.3 (22.7)
[11.7–106.1]
12/107 (11.2) 55 : 52 2.5-mg bolus
monthly+
≤ 25 µg per day
equivalent
Placebo+
10–25µg per
day equivalent
1 year ARI (1y) ARI: medical
record diagnosis
107/107 (100.0)
1y, primary outcome; 2y, secondary outcome; CLA, chemiluminescent assay; EIA, enzyme immunoassay; EQA, external quality assessment; ILI, influenza-like illness; LC-MS/MS, liquid
chromatography tandem-mass spectrometry; n/a, not applicable; RIA, radioimmunoassay; RIDT, rapid influenza diagnostic test.
a Sex missing for two participants randomised to intervention arm and subsequently excluded from analysis as a result of a lack of outcome data.
Notes
1 µg vitamin D3 = 40 IU.
25(OH)D concentrations reported in ng/ml were converted to nmol/l by multiplying by 2.496.
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TABLE 2 Risk-of-bias assessment
First author
and year
Sequence
generation
Allocation
concealment
Blinding of
participants
and personnel
Blinding of
outcome
assessment
Incomplete
outcome
data
Selective
reporting
Other
bias
Li-Ng 200953 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Urashima 201045 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Manaseki-
Holland 201054
✓ ✓ ✓ ✓ ✓ ✓ ✓
Laaksi 201055 ✓ ✓ ✓ ✓ ? ✓ ✓
Majak 201156 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Trilok Kumar
201157
✓ ✓ ✓ ✓ ✓ ✓ ✓
Lehouck 201228 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Manaseki-
Holland 201258
✓ ✓ ✓ ✓ ✓ ✓ ✓
Camargo 201239 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Murdoch 201240 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Bergman 201259 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Marchisio 201360 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Rees 201341 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Tran 201443 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Goodall 201461 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Urashima 201444 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Grant 201562 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Martineau
201529 (ViDiCO)
✓ ✓ ✓ ✓ ✓ ✓ ✓
Martineau
201547 (ViDiAs)
✓ ✓ ✓ ✓ ✓ ✓ ✓
Martineau
201548 (ViDiFlu)
✓ ✓ ✓ ✓ ✓ ✓ ✓
Simpson 201563 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Dubnov-Raz
201564
✓ ✓ ✓ ✓ ? ✓ ✓
Denlinger 201666 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Tachimoto
201642
✓ ✓ ✓ ✓ ✓ ✓ ✓
Kerley 201667 ✓ ✓ ✓ ✓ ? ✓ ✓
Jensen 201668 ✓ ✓ ✓ ✓ ✓ ✓ ✓
Ginde 201769 ✓ ✓ ✓ ✓ ✓ ✓ ✓
✓, low risk of bias; ?, unclear risk of bias.
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TABLE 3 One-step IPD meta-analysis, proportion of participants experiencing at least one ARI: overall and
by subgroup
Subgroup
Number
of trialsa
Proportion with ≥ 1 ARI subgroup (%)
aOR (95% CI)b p-value
p-value for
interactionControl Intervention
Overall 25 2204/5225 (42.2) 2303/5708 (40.3) 0.88 (0.81 to 0.96) 0.003 –
Baseline 25(OH)D (nmol/l)
< 25 14 137/249 (55.0) 117/289 (40.5) 0.58 (0.40 to 0.82) 0.002 0.01
≥ 25 19 1027/1639 (62.7) 1179/1995 (59.1) 0.89 (0.77 to 1.04) 0.15
Dosing regimen type
Bolus dose
≥ 30,000 IU
given
10 994/2786 (35.7) 1097/3014 (36.4) 0.97 (0.86 to 1.10) 0.67 0.05
Bolus dose
not given
15 1210/2439 (49.6) 1206/2694 (44.8) 0.81 (0.72 to 0.91) < 0.001
Daily dose equivalent (IU)
< 800 5 629/1321 (47.6) 619/1435 (43.1) 0.80 (0.68 to 0.94) 0.006 0.12
800–1999.9 9 945/2796 (33.8) 1023/3077 (33.2) 0.90 (0.79 to 1.01) 0.08
≥ 2000 11 630/1108 (56.9) 661/1196 (55.3) 0.98 (0.81 to 1.18) 0.84
Age (years)
≤ 1 4 832/2744 (30.3) 854/2827 (30.2) 0.94 (0.83 to 1.06) 0.33 0.61
1.1–15.9 8 241/513 (47.0) 194/566 (34.3) 0.60 (0.46 to 0.77) < 0.001
16–65 17 854/1459 (58.5) 885/1592 (55.6) 0.93 (0.79 to 1.10) 0.41
> 65 11 277/509 (54.4) 370/723 (51.2) 0.86 (0.67 to 1.09) 0.21
Body mass index (kg/m2)
< 25 19 972/1943 (50.0) 956/2074 (46.1) 0.85 (0.74 to 0.97) 0.02 0.29
≥ 25 17 659/1039 (63.4) 754/1235 (61.1) 0.95 (0.79 to 1.14) 0.58
Comorbidity: asthma
No 11 518/1008 (51.4) 520/1101 (47.2) 0.82 (0.68 to 0.99) 0.04 0.48
Yes 11 296/534 (55.4) 285/542 (52.6) 0.95 (0.73 to 1.25) 0.73
Comorbidity: COPD
No 7 477/763 (62.5) 493/791 (62.3) 1.00 (0.80 to 1.26) 0.98 0.38
Yes 6 122/230 (53.0) 120/238 (50.4) 0.84 (0.57 to 1.24) 0.38
Influenza vaccination
No 10 255/373 (68.4) 253/407 (62.2) 0.74 (0.52 to 1.03) 0.08 0.51
Yes 10 564/779 (72.4) 577/826 (69.9) 0.86 (0.68 to 1.09) 0.22
aOR, adjusted odds ratio.
a Some trials did not contribute data to a given subgroup, either because individuals within that subgroup were not
represented, or because data relating to the potential effect modifier were not recorded; accordingly the number of trials
represented varies between subgroups.
b Adjusted for age, sex and study duration.
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FIGURE 4 Cates plots illustrating reduction in risk of ARI with vitamin D supplementation, irrespective of dosing
frequency. (a) All participants, irrespective of baseline vitamin D status; (b) participants with baseline serum 25(OH)D
concentration of < 25 nmol/l; and (c) participants receiving daily or weekly vitamin D supplementation regimens
without any additional bolus doses.
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Overall results: asthma exacerbation
One-step IPD meta-analysis testing the effects of vitamin D on the rate of asthma exacerbations requiring
treatment with systemic corticosteroids revealed a statistically significant protective effect of the intervention
(aIRR 0.74, 95% CI 0.56 to 0.97; p= 0.03; 955 participants in seven studies). Two-step IPD meta-analysis
revealed a similar effect size (aIRR 0.69, 95% CI 0.52 to 0.92, p= 0.01; p for heterogeneity = 0.56; 719
participants in four studies). Consistent trends were seen for analysis of the proportion of participants
experiencing at least one asthma exacerbation requiring treatment with systemic corticosteroids in both
one-step analysis (aOR 0.75, 95% CI 0.51 to 1.09; p= 0.13; 955 participants in seven studies) and two-step
analysis (aOR 0.69, 95% CI 0.46 to 1.02, p= 0.06; p for heterogeneity = 0.74; 719 participants in four studies).
TABLE 4 One-step IPD meta-analysis, ARI event rate: overall effect and subgroup analyses by baseline vitamin D
status and dosing regimen
Subgroup
Number
of trials
Number of
individuals
Rate of ARI per
participant-year, subgroup
aIRR (95% CI)a p-value
p-value for
InteractionControl Intervention
Overall 25 10,703 1.15 1.13 0.96 (0.92 to 0.997) 0.04 –
Baseline 25(OH)D (nmol/l)
< 25 14 509 2.15 1.67 0.78 (0.66 to 0.93) 0.004 0.02
≥ 25 19 3458 2.12 1.91 0.95 (0.90 to 1.00) 0.04
Dosing regimen type
Bolus dose
≥ 30,000 IU
given
10 5595 0.73 0.76 0.99 (0.94 to 1.05) 0.83 0.11
Bolus dose
not given
15 5133 2.23 2.09 0.93 (0.88 to 0.98) 0.008
a Adjusted for age, sex and study duration.
TABLE 5 One-step IPD meta-analysis, time to first ARI: overall effect and subgroup analyses by baseline vitamin D
status and dosing regimen
Subgroup
Number
of trials
Number of
individuals
Median time (days) to first ARI,
subgroup (IQR)
aHR (95% CI)a p-value
p-value for
InteractionControl Intervention
Overall 18 9108 452 (79 to –) 502 (81 to –) 0.95 (0.89 to 1.01) 0.09 –
Baseline 25(OH)D (nmol/l)
< 25 10 229 159 (56 to –) 172 (74 to –) 0.92 (0.66 to 1.28) 0.62 0.61
≥ 25 12 2231 104 (41 to 280) 110 (40 to 328) 0.97 (0.88 to 1.06) 0.48
Dosing regimen type
Bolus dose
≥ 30,000 IU
given
8 4795 – (121 to –) – (117 to –) 0.98 (0.89 to 1.08) 0.74 0.30
Bolus dose
not given
10 4313 138 (57 to 331) 153 (61 to 351) 0.91 (0.84 to 0.99) 0.04
–, these values cannot be defined.
a Adjusted for age, sex and study duration.
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FIGURE 5 Two-step IPD meta-analysis, proportion of participants experiencing at least one ARI. Data from the trial by Simpson et al.63 were not included in this two-step
meta-analysis, as an estimate for the effect of the intervention in the study could not be obtained in the regression model because of the small sample size.
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Similarly, trends towards a delay to first exacerbation with vitamin D versus placebo were seen in both one-step
analysis (aHR 0.78, 95% CI 0.55 to 1.10; p= 0.16; 868 participants in five studies) and two-step analysis
(aHR 0.74, 95% CI 0.52 to 1.05, p= 0.09; p for heterogeneity = 0.58; 680 participants in three studies).
Overall results: chronic obstructive pulmonary disease exacerbation
One-step IPD meta-analysis testing the effects of vitamin D on the rate of COPD exacerbations requiring
treatment with antibiotics and/or systemic corticosteroids did not reveal a statistically significant protective
effect of the intervention overall (aIRR 0.95, 95% CI 0.82 to 1.10; p = 0.50; 422 participants in two studies).
Two-step IPD meta-analysis revealed a similar estimate (aIRR 0.96, 95% CI 0.83 to 1.10; p = 0.54; 422
participants in two studies). Consistent results were seen for analysis of the proportion of participants
experiencing at least one study-defined exacerbation in both one-step IPD meta-analysis (aOR 0.80, 95% CI
0.51 to 1.25; p = 0.32; 422 participants in two studies) and two-step IPD meta-analysis (aOR 0.79, 95% CI
0.50 to 1.24; p = 0.31; 422 participants in two studies). Similarly, no statistically significant effects of the
intervention on time to first exacerbation were seen for one-step IPD meta-analysis (aHR 0.95, 95% CI 0.75
to 1.21; p = 0.67; 422 participants in two studies) or two-step IPD meta-analysis (aHR 0.96, 95% CI 0.76 to
1.22; p = 0.75; 422 participants in two studies) overall.
Subgroup analyses: acute respiratory infection incidence
In order to explore reasons for heterogeneity, subgroup analyses were conducted to investigate whether or
not the effects of vitamin D supplementation on ARI risk differed according to baseline vitamin D status,
dosing frequency, dose size, age, body mass index, the presence or absence of comorbidity (asthma or
COPD) or influenza vaccination status. Race/ethnicity was not investigated as a potential effect-modifier,
as data for this variable were missing for 3680 out of 10,933 (34%) participants, and power for subgroup
analyses was limited by small numbers in many racial/ethnic subgroups that could not be meaningfully
combined. Similarly, baseline data relating to environmental exposure to particulate matter, nutritional
supplement use and vitamin D-related genotype were unavailable or available only in a very small number
of studies, precluding investigation of these factors as potential effect modifiers. The results are presented
in Overall results: acute respiratory infection incidence (see Table 3). Subgroup analysis revealed a strong
protective effect of vitamin D supplementation among individuals at a baseline circulating 25(OH)D
concentration level of < 25 nmol/l (aOR 0.58, 95% CI 0.40 to 0.82; NNT 8, 95% CI 5 to 21; 538 participants
in 14 studies; within subgroup, p = 0.002; Cates plot, see Figure 4), and no statistically significant effect
among those at a baseline 25(OH)D concentration level of ≥ 25 nmol/l (aOR 0.89, 95% CI 0.77 to 1.04;
3634 participants in 19 studies; within subgroup, p = 0.15; for interaction, p = 0.01). This evidence was
assessed as being of high quality.
A meta-analysis of data from trials in which vitamin D was administered using a daily or weekly regimen
without additional bolus doses revealed a protective effect of vitamin D against ARI (aOR 0.81, 95% CI
0.72 to 0.91; NNT 20, 95% CI 13 to 43; 5133 participants in 15 studies; within subgroup, p < 0.001;
Cates plot, see Figure 4). No such protective effect was seen among participants in trials in which at least
one bolus dose of vitamin D was administered (aOR 0.97, 95% CI 0.86 to 1.10; 5800 participants in
10 studies; within subgroup, p = 0.67; for interaction, p = 0.05). This evidence was assessed as being of
high quality. The p-values for interaction were > 0.05 for all other potential effect modifiers investigated.
For both of these subgroup analyses, broadly consistent effects were observed for event rate analysis
(see Table 4) and survival analysis (see Table 5).
Having identified two potential factors that modified the influence of vitamin D supplementation on the risk
of ARI (i.e. baseline vitamin D status and dosing frequency), we then proceeded to investigate whether or
not these factors were acting as independent effect modifiers, and whether or not they were confounded by
each other or by another potential effect modifier, such as age. Dot plots revealed a trend towards lower
median baseline serum 25(OH)D concentration and higher median age for studies employing bolus versus
daily or weekly dosing (Figures 6 and 7). In order to establish which of these potential effect modifiers
was acting independently, we repeated the analysis to include treatment–covariate interaction terms for
baseline vitamin D status, dosing frequency and age. In this model, interaction terms for baseline vitamin D
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status and dosing frequency were statistically significant (p = 0.01 and p = 0.004, respectively), but the
interaction term for age was not statistically significant (p = 0.20), consistent with the hypothesis that
baseline vitamin D status and dosing frequency, but not age, independently modified the effect of vitamin D
supplementation on ARI risk.
We then proceeded to stratify the subgroup analysis presented in Table 3 according to dosing frequency,
in order to provide a ‘cleaner’ look at the results of the subgroup analyses under the assumption that
administration of bolus doses was ineffective. The results of this exploratory analysis are presented in Table 6.
This analysis reveals that daily or weekly administration of vitamin D was associated with an even greater
degree of protection against ARI among participants with baseline circulating 25(OH)D concentrations of
< 25 nmol/l than in the unstratified analysis (aOR 0.30, 95% CI 0.17 to 0.53; NNT 4, 95% CI 3 to 7;
234 participants in six studies; within subgroup, p < 0.001; Cates plot, Figure 8). Moreover, administration
of daily or weekly vitamin D also protected against ARI among participants with higher baseline 25(OH)D
concentrations (aOR 0.75, 95% CI 0.60 to 0.95; NNT 15, 95% CI 9 to 86; 1603 participants in six
studies; within subgroup, p = 0.02; Cates plot, see Figure 8). The p-value for interaction for this subgroup
analysis was 0.006, indicating that protective effects of daily or weekly vitamin D supplementation
were significantly greater in the subgroup of participants with profound vitamin D deficiency. No other
statistically significant interaction was seen; notably, bolus-dose vitamin D supplementation did not offer
any protection against ARI even when administered to those with circulating 25(OH)D concentrations of
< 25 nmol/l (aOR 0.82, 95% CI 0.51 to 1.33; 304 participants in eight studies; within subgroup, p = 0.43).
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FIGURE 6 Mean baseline serum 25(OH)D concentration at enrolment by dosing regimen. Bolus, studies in which a
bolus dose of ≥ 30,000 IU of vitamin D was given in the intervention arm; No bolus, studies in which vitamin D was
administered daily or weekly without administration of a bolus dose.
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FIGURE 7 Mean age at enrolment by dosing regimen. Bolus, studies in which a bolus dose of ≥ 30,000 IU of vitamin D
was given in the intervention arm; No bolus, studies in which vitamin D was administered daily or weekly without
administration of a bolus dose.
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TABLE 6 One-step IPD meta-analysis, proportion of participants experiencing at least one ARI: overall and by subgroup, stratified by dosing frequency
Subgroup
Bolus Daily or weekly
Number
of trialsa
Proportion with ≥ 1 ARI
subgroup (%)
aOR (95% CI)b p-value
p-value for
interaction
Number
of trialsa
Proportion with ≥ 1 ARI
subgroup (%)
aOR (95% CI)b p-value
p-value for
interactionControl Intervention Control Intervention
Overall 10 994/2786 (35.7) 1097/3014 (36.4) 0.97 (0.86 to 1.10) 0.67 N/A 15 1210/2439 (49.6) 1206/2694 (44.8) 0.81 (0.72 to 0.91) 0.001 N/A
Baseline 25(OH)D (nmol/l)
< 25 8 73/142 (51.4) 77/162 (47.5) 0.82 (0.51 to 1.33) 0.43 0.42 6 64/107 (59.8) 40/127 (31.5) 0.30 (0.17 to 0.53) < 0.001 0.006
≥ 25 8 550/910 (60.4) 663/1121 (59.1) 1.02 (0.83 to 1.24) 0.87 11 477/729 (65.4) 516/874 (59.0) 0.75 (0.60 to 0.95) 0.02
Daily dose equivalent (IU)
< 800 0 N/A N/A N/A N/A 0.56 5 629/1321 (47.6) 619/1435 (43.1) 0.80 (0.68 to 0.94) 0.006 0.82
800–1999.9 3 467/1931 (24.2) 542/2127 (25.5) 0.95 (0.81 to 1.10) 0.50 6 478/865 (55.3) 481/950 (50.6) 0.81 (0.66 to 1.01) 0.06
≥ 2000 7 527/855 (61.6) 555/887 (62.6) 1.03 (0.83 to 1.28) 0.81 4 103/253 (40.7) 106/309 (34.3) 0.85 (0.58 to 1.24) 0.39
Age (years)
≤ 1 2 321/1634 (19.6) 322/1637 (19.7) 0.99 (0.83 to 1.19) 0.93 0.72 2 511/1110 (46.0) 532/1190 (44.7) 0.91 (0.77 to 1.08) 0.30 0.37
1.1–15.9 1 50/100 (50.0) 35/93 (37.6) 0.62 (0.35 to 1.11) 0.11 7 191/413 (46.2) 159/473 (33.6) 0.59 (0.45 to 0.79) < 0.001
16–65 8 432/678 (63.7) 466/716 (65.1) 1.15 (0.90 to 1.48) 0.27 9 422/781 (54.0) 419/876 (47.8) 0.79 (0.63 to 0.99) 0.04
> 65 8 191/374 (51.1) 274/568 (48.2) 0.85 (0.65 to 1.12) 0.25 3 86/135 (63.7) 96/155 (61.9) 0.88 (0.52 to 1.52) 0.66
Body mass index (kg/m2)
< 25 8 215/372 (57.8) 231/417 (55.4) 1.01 (0.72 to 1.40) 0.97 0.70 11 757/1571 (48.2) 725/1657 (43.8) 0.82 (0.71 to 0.95) 0.009 > 0.99
≥ 25 8 406/677 (60.0) 509/867 (58.7) 1.00 (0.80 to 1.25) 0.98 9 253/358 (70.7) 245/367 (66.8) 0.83 (0.59 to 1.17) 0.30
Asthma
No 5 303/484 (62.6) 323/523 (61.8) 0.95 (0.71 to 1.28) 0.75 0.40 6 215/524 (41.0) 197/578 (34.1) 0.74 (0.58 to 0.95) 0.02 0.40
Yes 4 224/371 (60.4) 232/364 (63.7) 1.18 (0.85 to 1.65) 0.32 7 72/163 (44.2) 53/178 (29.8) 0.60 (0.37 to 0.98) 0.04
COPD
No 5 410/632 (64.9) 436/656 (66.5) –c –c –c 2 67/131 (51.1) 57/135 (42.2) –c –c –c
Yes 4 117/223 (52.5) 119/231 (51.5) –c –c –c 2 5/7 (71.4) 1/7 (14.3) –c –c –c
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Subgroup
Bolus Daily or weekly
Number
of trialsa
Proportion with ≥ 1 ARI
subgroup (%)
aOR (95% CI)b p-value
p-value for
interaction
Number
of trialsa
Proportion with ≥ 1 ARI
subgroup (%)
aOR (95% CI)b p-value
p-value for
interactionControl Intervention Control Intervention
Influenza vaccination
No 5 119/163 (73.0) 121/178 (68.0) –c –c –c 5 136/210 (64.8) 132/229 (57.6) –c –c –c
Yes 5 286/396 (72.2) 294/421 (69.8) 5 278/383 (72.6) 283/405 (69.9)
N/A, not applicable.
a Some trials did not contribute data to a given subgroup, either because individuals within that subgroup were not represented, or because data relating to the potential effect modifier
were not recorded; accordingly, the number of trials represented varies between subgroups.
b Adjusted for age, sex and study duration.
c Values could not be estimated as models did not converge.
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Subgroup analyses: asthma exacerbation
Subgroup analyses were conducted to investigate whether or not the effects of vitamin D supplementation
on the rate of asthma exacerbations requiring treatment with systemic corticosteroids differed according to
baseline vitamin D status, age, body mass index, administration of bolus doses of vitamin D, amount of
vitamin D administered and concomitant use of inhaled corticosteroids. The results are presented in Table 7.
Vitamin D supplementation reduced the rate of asthma exacerbations requiring treatment with systemic
corticosteroids among individuals with baseline circulating 25(OH)D concentrations of < 25 nmol/l (aIRR 0.33,
95% CI 0.11 to 0.98; 92 participants in three studies; within subgroup, p = 0.046) and in those with baseline
25(OH)D concentrations of ≥ 25 nmol/l (aIRR 0.77, 95% CI 0.58 to 1.03; 764 participants in six studies
within subgroup, p = 0.08). The treatment–covariate interaction term (ratio of aIRRs) for this subgroup
analysis was 0.56 (95% CI 0.20 to 1.52; for interaction, p = 0.25). The p-values for interaction for all other
subgroup analyses were also > 0.05.
(a)
Good outcome
Key
Bad outcome
Better with treatment
(b)
Good outcome
Key
Bad outcome
Better with treatment
FIGURE 8 Cates plot illustrating reduction in risk of ARI with daily or weekly vitamin D supplementation
without additional bolus doses. (a) Participants with baseline serum 25(OH)D concentrations of < 25 nmol/l;
and (b) participants with baseline serum 25(OH)D concentrations of ≥ 25 nmol/l.
RESULTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
TABLE 7 One-step IPD meta-analysis, rate of asthma exacerbations requiring treatment with systemic
corticosteroids: overall and by subgroup
Subgroup
Number
of trialsa
Number of
individuals
Event rate per participant-year
subgroup
aIRR (95% CI)b p-value
p-value for
interactionControl Intervention
Overall 7 955 121/284.7 (0.43) 85/286.6 (0.30) 0.74 (0.56 to 0.97) 0.03 –
Baseline 25(OH)D (nmol/l)
< 25 3 92 14/33.0 (0.42) 6/32.2 (0.19) 0.33 (0.11 to 0.98) 0.046 0.25
≥ 25 6 764 107/233.8 (0.46) 79/240.2 (0.33) 0.77 (0.58 to 1.03) 0.08
Age (years)
< 16 5 290 26/57.6 (0.45) 19/61.8 (0.31) 0.64 (0.34 to 1.20) 0.16 0.56
≥ 16 3 665 95/227.2 (0.42) 66/224.7 (0.29) 0.70 (0.51 to 0.97) 0.03
Sex
Female 7 547 80/163.6 (0.49) 47/167.7 (0.28) 0.61 (0.43 to 0.88) 0.008 0.17
Male 7 408 41/121.1 (0.34) 38/118.7 (0.32) 0.91 (0.58 to 1.42) 0.67
Body habitus
Not
overweight
7 381 38/110.5 (0.34) 26/104.5 (0.25) 0.91 (0.55 to 1.51) 0.71 0.31
Overweightc 7 574 83/174.3 (0.48) 59/182.0 (0.32) 0.68 (0.49 to 0.95) 0.02
Bolus-dose vitamin D given
No 4 275 13/53.8 (0.24) 10/58.9 (0.17) 0.65 (0.26 to 1.63) 0.36 0.49
Yes 3 680 108/230.9 (0.47) 75/227.6 (0.33) 0.71 (0.52 to 0.95) 0.02
Daily dose equivalent (IU)
< 2000 4 258 13/52.1 (0.25) 10/58.6 (0.17) 0.62 (0.26 to 1.44) 0.26 0.78
≥ 2000 3 697 108/232.7 (0.46) 75/228.0 (0.33) 0.73 (0.54 to 0.98) 0.03
Inhaled corticosteroids
No 4 92 1/18.8 (0.05) 4/26.1 (0.15) 1.11 (0.07 to 18.40) 0.94 0.19
Yes 5 764 120/248.0 (0.48) 81/246.3 (0.33) 0.71 (0.54 to 0.95) 0.02
Study duration (months)
< 6 2 138 13/25.0 (0.52) 9/19.4 (0.46) 0.50 (0.18 to 1.37) 0.18 0.62
≥ 6 5 816 108/259.8 (0.42) 76/267.2 (0.28) 0.72 (0.53 to 0.96) 0.03
a Some trials did not contribute data to a given subgroup, either because individuals within that subgroup were not
represented, or because data relating to the potential effect modifier were not available; accordingly, the number of
trials represented varies between subgroups.
b Adjusted for age and sex.
c Overweight defined as body mass index z-score ≥ 1.0 for participants aged < 19 years and as body mass index
≥ 25 kg/m2 for participants aged ≥ 19 years.
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Subgroup analyses: chronic obstructive pulmonary disease exacerbation
Subgroup analyses were conducted to investigate whether or not the effects of vitamin D supplementation
on the rate of study-defined COPD exacerbation differed according to baseline vitamin D status, COPD
severity, inhaled corticosteroid requirement at baseline and body mass index. The results are presented in
Table 8. Vitamin D supplementation reduced the rate of COPD exacerbations among individuals with baseline
circulating 25(OH)D concentrations of < 25 nmol/l (aIRR 0.56, 95% CI 0.39 to 0.81; 81 participants in two
studies; within subgroup, p= 0.002) but not in those with baseline 25(OH)D concentrations of ≥ 25 nmol/l
(aIRR 1.05, 95% CI 0.89 to 1.23; 341 participants in two studies; within subgroup, p = 0.65).
The treatment–covariate interaction term (ratio of aIRRs) for this subgroup analysis was 1.85 (95% CI 1.24
to 2.75; for interaction, p = 0.003). The p-values for interaction for other subgroup analyses were > 0.05.
Secondary outcomes: efficacy
Results of one-step IPD meta-analysis of secondary outcomes are presented in Table 9.
When all studies were analysed together, no statistically significant effect of vitamin D was seen on the
proportion of participants with at least one URI, LRI, hospitalisation or emergency department attendance
for ARI, use of a course of antimicrobials for ARI, work/school absence as a result of ARI, severe asthma
exacerbation or severe COPD exacerbation. When this analysis was stratified by dosing frequency in an
exploratory analysis, a borderline significant protective effect of daily or weekly vitamin D supplementation
against URI was seen (aOR 0.88, 95% CI 0.78 to 1.00; 4483 participants in 11 studies, p = 0.05; Table 10).
TABLE 8 One-step IPD meta-analysis, COPD exacerbation rate: overall and by subgroup
Subgroup
Number
of trials
Number of
individuals
Event rate per participant-year,
group subgroup
aIRR (95% CI)a p-value
p-value for
interactionControl Intervention
Overall 2 422 374/189.75 (1.97) 364/193.67 (1.88) 0.95 (0.82 to 1.10) 0.50
Baseline 25(OH)D (nmol/l)
< 25 2 81 76/35.87 (2.12) 46/39.45 (1.16) 0.56 (0.39 to 0.81) 0.002 0.003
≥ 25 2 341 298/153.88 (1.94) 318/154.23 (2.06) 1.05 (0.89 to 1.23) 0.56
COPD severity
GOLD
stage 1/2
2 223 123/100.82 (1.22) 130/104.25 (1.25) 1.03 (0.81 to 1.32) 0.79 0.45
GOLD
stage 3/4
2 199 251/88.93 (2.82) 234/89.42 (2.62) 0.92 (0.77 to 1.10) 0.37
Concomitant inhaled corticosteroid at baseline
No 2 112 55/45.31 (1.21) 55/53.53 (1.03) 0.91 (0.62 to 1.32) 0.61 0.70
Yes 2 310 319/144.44 (2.21) 309/140.14 (2.20) 0.97 (0.83 to 1.14) 0.72
Body mass index (kg/m2)
< 25 2 199 200/97.92 (2.04) 172/82.07 (2.10) 0.99 (0.81 to 1.21) 0.91 0.70
≥ 25 2 223 174/91.83 (1.89) 192/111.60 (1.72) 0.92 (0.75 to 1.13) 0.42
GOLD, Global Initiative for Chronic Obstructive Lung Disease.
a Adjusted for age, sex and COPD severity.
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Secondary outcomes: safety
Administration of vitamin D did not influence the risk of serious adverse events of any cause (aOR 0.98,
95% CI 0.80 to 1.20) or death attributable to any cause (aOR 1.39, 95% CI 0.85 to 2.27) (see Table 9).
Instances of potential adverse reactions to vitamin D were rare. Hypercalcaemia was detected in 21 out
of 3850 (0.5%) and renal stones were diagnosed in 6 out of 3841 (0.2%); both events were equally
represented in the intervention and control arms (see Table 9). Stratification of this analysis by dosing
frequency did not reveal any statistically significant increase in the risk of adverse events with either bolus
or daily or weekly supplementation (see Table 10).
Risk of bias across studies
A funnel plot for the proportion of participants experiencing at least one ARI showed a degree of asymmetry,
raising the possibility that small trials showing adverse effects of vitamin D may not have been included in the
meta-analysis (Figure 9).
Responder analyses
The results of responder analyses for the outcome of the proportion of participants with at least one ARI
are presented in Table 11. Among participants randomised to the intervention arm of included studies for
whom end-study 25(OH)D concentration data were available, no difference in risk of ARI was observed
between those who attained a serum 25(OH)D concentration of ≥ 75 nmol/l and those who did not.
TABLE 9 One-step IPD meta-analysis of secondary outcomes
Outcome
Number
of trials
Proportion with ≥ 1 event
subgroup (%)
aOR (95% CI)a p-valueControl Intervention
URI 19 1656/3286 (50.4) 1807/3733 (48.4) 0.93 (0.83 to 1.03) 0.15
LRI 9 542/3285 (16.5) 561/3413 (16.4) 0.96 (0.83 to 1.10) 0.52
Hospitalisation or emergency
department attendance as a result
of ARI
11 47/3886 (1.2) 40/3986 (1.0) 0.83 (0.54 to 1.27) 0.39
Use of antimicrobials for treatment
of ARI
9 397/983 (40.4) 413/1121 (36.8) 0.84 (0.69 to 1.03) 0.10
Work/school absence as a result of
ARI
7 321/632 (50.8) 319/684 (46.6) 0.87 (0.69 to 1.09) 0.22
Serious adverse event of any cause 25 216/5371 (4.0) 221/5853 (3.8) 0.98 (0.80 to 1.20) 0.83
Death as a result of ARI/respiratory
failure
25 7/5330 (0.1) 6/5802 (0.1) 0.70 (0.23 to 2.20) 0.55
Death as a result of any infection 25 15/5338 (0.3) 16/5812 (0.3) 0.95 (0.46 to 1.99) 0.90
Death as a result of any cause 25 48/5371 (0.9) 56/5853 (1.0) 1.39 (0.85 to 2.27) 0.18
Hypercalcaemia 14 9/1739 (0.5) 12/2111 (0.6) –b –b
Renal stones 14 4/1707 (0.2) 2/2134 (0.1) –b –b
a Adjusted for age, sex and study duration.
b Values could not be estimated as models did not converge.
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TABLE 10 One-step IPD meta-analysis of secondary outcomes, stratified by dosing frequency
Outcome
Bolus dosing Daily or weekly dosing
Number
of trials
Proportion with ≥ 1 event
subgroup (%)
aOR (95% CI)a p-value
Number
of trials
Proportion with ≥ 1 event
subgroup (%)
aOR (95% CI)a p-valueControl Intervention Control Intervention
URI 8 606/1052 (57.6) 730/1284 (56.9) 1.03 (0.86 to 1.24) 0.72 11 1050/2234 (47.0) 1077/2449 (44.0) 0.88 (0.78 to 1.00) 0.05
LRI 4 424/1889 (22.4) 427/1922 (22.2) 0.96 (0.82 to 1.13) 0.60 5 118/1396 (8.5) 134/1491 (9.0) 0.98 (0.75 to 1.28) 0.88
Use of antimicrobials
for treatment of ARI
4 201/348 (57.8) 203/367 (55.3) 0.79 (0.56 to 1.10) 0.16 5 196/635 (30.9) 210/754 (27.9) 0.87 (0.67 to 1.13) 0.31
Work/school absence
as a result of ARI
4 219/409 (53.5) 196/411 (47.7) 0.78 (0.59 to 1.04) 0.10 3 102/223 (45.7) 123/273 (45.1) 1.03 (0.71 to 1.48) 0.88
Severe asthma
exacerbation
3 73/343 (21.3) 57/337 (16.9) 0.72 (0.49 to 1.07) 0.11 4 8/140 (5.7) 6/146 (4.1) 0.73 (0.19 to 2.85) 0.65
Severe COPD
exacerbation
2 140/207 (67.6) 133/213 (62.4) 0.77 (0.50 to 1.20) 0.25 0 – – – –
Serious adverse event
of any cause
10 107/2822 (3.8) 115/3070 (3.8) 1.00 (0.74 to 1.35) 0.99 15 109/2549 (4.3) 106/2783 (3.8) 0.97 (0.73 to 1.30) 0.86
Death as a result of
any cause
10 29/2822 (1.0) 35/3070 (1.1) 1.29 (0.71 to 2.35) 0.40 15 19/2549 (0.7) 21/2783 (0.8) –b –b
Death as a result of
ARI/respiratory failure
10 4/2797 (0.1) 3/3038 (0.1) 0.61 (0.12 to 3.02) 0.54 15 3/2533 (0.1) 3/2765 (0.1) –b –b
Death as a result of
any infection
10 8/2801 (0.3) 5/3040 (0.2) 0.55 (0.17 to 1.80) 0.32 15 7/2537 (0.3) 11/2773 (0.4) –b –b
Hospitalisation or
emergency department
attendance as a result
of ARI
6 4/2081 (0.2) 6/2124 (0.3) –b –b 5 43/1805 (2.4) 34/1862 (1.8) –b –b
Hypercalcaemia 8 8/1062 (0.8) 11/1303 (0.8) –b –b 6 1/677 (0.1) 1/808 (0.1) –b –b
Renal stones 6 0/764 (0.0) 1/1011 (0.1) –b –b 8 4/943 (0.4) 1/1123 (0.1) –b –b
a Adjusted for age, sex and study duration.
b Values could not be estimated as model did not converge.
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Sensitivity analyses
A meta-analysis using IPD of the proportion of participants experiencing at least one ARI, excluding
two trials assessed as being at an unclear risk of bias,55,64 revealed protective effects of vitamin D
supplementation consistent with the main analysis (aOR 0.82, 95% CI 0.70 to 0.95; 10,744 participants;
p = 0.01). Sensitivity analyses for the same outcome, restricted to the 14 trials that investigated ARI as a
primary or coprimary outcome, also revealed protective effects of vitamin D supplementation consistent
with the main analysis (aOR 0.82, 95% CI 0.68 to 1.00; 5739 participants; p = 0.05).
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FIGURE 9 Funnel plot with pseudo 95% confidence limits for IPD meta-analysis of proportion of participants
experiencing at least one ARI.
TABLE 11 Responder analyses, one-step IPD meta-analysis for the outcome of ARI
25(OH)D status
Number of
trials Impact on ARI Ratio p-value
Proportion with
≥ 1 ARI (%) aOR (95% CI)a
Intervention, end-study 25(OH)D
level of < 75 nmol/l
18 542/1120 (48.4) 1 –
Intervention, end-study 25(OH)D
level of ≥ 75 nmol/l
18 784/1291 (60.7) 0.96 (0.78 to 1.18) 0.68
Median time (days)
to first ARI (IQR) aHR (95% CI)
Intervention, end-study 25(OH)D
level of < 75 nmol/l
11 190 (63, –)b 1 –
Intervention, end-study 25(OH)D
level of ≥ 75 nmol/l
12 102 (39–312) 1.02 (0.88 to 1.19) 0.76
Rate of ARI per
participant-year aIRR (95% CI)
Intervention, end-study 25(OH)D
level of < 75 nmol/l
18 1.51 1 –
Intervention, end-study 25(OH)D
level of ≥ 75 nmol/l
18 2.04 1.01 (0.94 to 1.10) 0.72
IQR, interquartile range.
a Adjusted for age, sex and study duration.
b The 75th percentile for time to first ARI in this group cannot be defined.
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Chapter 5 Discussion
Principal findings
We report the results of the first IPD meta-analysis of RCTs of vitamin D to prevent ARI. In the study
population as a whole, vitamin D supplementation reduced the risk of experiencing at least one ARI.
Subgroup analysis revealed that daily or weekly vitamin D supplementation without additional bolus doses
protected against ARI, while regimens containing large bolus doses did not. Among those receiving daily
or weekly vitamin D, protective effects of vitamin D were strongest in individuals with profound vitamin D
deficiency at baseline, although those with higher baseline 25(OH)D concentrations also experienced benefit.
This evidence was assessed as being of high quality, using the GRADE criteria.52 As baseline vitamin D status
and use of bolus doses varied significantly between studies, our results suggest that the high degree of
heterogeneity between trials may be at least partly attributable to these factors. Administration of vitamin D
was safe: potential adverse reactions were very rare, and the risk of such events was the same among both
participants randomised to intervention arms and those randomised to control arms.
Why might administration of a bolus dose of vitamin D be ineffective for prevention of ARI? One
explanation relates to potentially adverse effects of wide fluctuations in circulating 25(OH)D concentrations,
which are seen following administration of bolus doses but not with daily or weekly supplementation.
Vieth70 has proposed that high circulating 25(OH)D concentrations following bolus dosing may chronically
dysregulate activity of the enzymes responsible for synthesis and degradation of the active vitamin D
metabolite 1,25-dihydroxyvitamin D, resulting in decreased concentrations of this metabolite in extrarenal
tissues. Such an effect could attenuate the ability of 25(OH)D to support protective immune responses to
respiratory pathogens. Increased efficacy of vitamin D supplementation in individuals with lower baseline
vitamin D status is more readily explicable, based on the principle that individuals who are the most
deficient in a micronutrient will be the most likely to respond to its replacement.
One question raised by our results relates to whether or not vitamin D supplementation will be more
beneficial in reducing ARI risk for individuals or for the population as a whole. A targeted approach aimed
at individuals would involve testing baseline vitamin D status and offering supplements to those who
are deficient. This approach would be likely to result in relatively good adherence (motivation to take a
supplement will be higher if an individual knows that they are deficient), but it will be costly and it may
not reach a large proportion of the people who stand to benefit. Making additional vitamin D available to
the population as a whole in an untargeted fashion (e.g. via food fortification) has some inefficiencies, in
that some vitamin D-replete individuals will receive extra vitamin D unnecessarily. However, the strategy
also has potential advantages, in that it would provide superior coverage to a ‘test-and-treat’ approach.
The relative merits of the two strategies need to be formally evaluated with a health economic analysis,
as suggested in Future research.
Our study also investigated the effects of vitamin D supplementation on the risk of acute exacerbations of
asthma and COPD. Vitamin D supplementation reduced the rate of asthma exacerbation requiring treatment
with systemic corticosteroids overall; non-statistically significant trends towards protection were also seen when
the outcome of asthma exacerbation was analysed as the proportion of participants with at least one event
and the time to first event. Subgroup analyses for this outcome revealed a trend towards greater protection in
participants with a baseline 25(OH)D concentration level of < 25 nmol/l than in those with a higher baseline
25(OH)D concentration level; however, the p-value for interaction for this subgroup analysis was 0.25, indicating
that we found no statistically significant evidence to implicate baseline vitamin D status as an effect modifier.
By contrast, vitamin D supplementation had no statistically significant effect on the risk of COPD exacerbation
requiring treatment with antibiotics and/or systemic corticosteroids overall. Subgroup analyses for this outcome
revealed a strong protective effect in individuals with baseline 25(OH)D concentrations of < 25 nmol/l, but no
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protective effect among individuals with higher baseline 25(OH)D concentration levels. The p-value for
interaction for this subgroup analysis was 0.003, indicating that baseline vitamin D status modifies the effects of
vitamin D supplementation on the risk of COPD exacerbation.
Strengths and limitations
Our study has several strengths. We obtained IPD for all 25 trials identified by our search, the proportion
of randomised participants with missing outcome data was small (3.4%), participants with diverse
characteristics in multiple settings were represented and 25(OH)D concentration levels were measured
using validated assays in laboratories that participated in external quality-assessment schemes. Our findings
therefore have a high degree of internal and external validity. Moreover, the subgroup effects we report
fulfil published ‘credibility criteria’ relating to study design, analysis and context.71 Specifically, the relevant
effect modifiers were specified a priori and measured at baseline, p-values for interaction remained
significant after adjustment for potential confounders and subgroup effects were consistent when analysed
as proportions and event rates. Survival analysis revealed consistent trends that did not attain statistical
significance, possibly owing to lack of power (fewer studies contributed data to survival analyses than to
analyses of proportions and event rates). As discussed above, the concepts that vitamin D supplementation
may be (1) more effective when given to those with lower baseline 25(OH)D concentration levels and
(2) less effective when bolus doses are administered are also biologically plausible. Although the results are
consistent with the hypothesis that baseline vitamin D status and dosing regimen independently modify
effects of vitamin D supplementation, we cannot exclude the possible influence of other effect modifiers
linked to these two factors. The risk of residual confounding by other effect modifiers is increased for
analyses in which relatively few trials are represented within a subgroup, for example when subgroup
analyses were stratified by dosing regimen. We therefore suggest caution when interpreting the results in
Tables 6 and 10.
Our study has some limitations. One explanation for the degree of asymmetry seen in the funnel plot
(see Figure 9) is that some small trials showing adverse effects of vitamin D may have escaped our attention.
With regard to the potential for missing data, we made strenuous efforts to identify published and (at the
time) unpublished data, as illustrated by the fact that our meta-analysis includes data from 25 studies,
which is 10 more than the largest aggregate data meta-analysis in the field.24 However, if one or two small
trials showing large adverse effects of vitamin D were to emerge, we do not anticipate that they would
greatly alter the results of the one-step IPD meta-analysis, as any negative signal from a modest number of
additional participants would probably be diluted by the robust protective signal generated from analysis of
data from nearly 11,000 participants. A second limitation is that our power to detect effects of vitamin D
supplementation was limited for some subgroups [e.g. individuals with baseline 25(OH)D concentration of
< 25 nmol/l on bolus dosing regimens] and for some secondary outcomes (e.g. incidence of LRI). Null and
borderline significant results for analyses of these outcomes may have arisen as a consequence of type II
error. Additional RCTs investigating the effects of vitamin D on the risk of ARI and exacerbation of asthma
and COPD are ongoing, and inclusion of data from these studies in future meta-analyses has the potential to
increase statistical power to test for subgroup effects. However, all three of the largest such studies for ARI
prevention (NCT01169259, ACTRN12611000402943 and ACTRN12613000743763) are being conducted
in populations in which profound vitamin D deficiency is rare, and two are using intermittent bolus dosing
regimens (ACTRN12611000402943 and ACTRN12613000743763): their results are therefore unlikely
to alter our finding of benefit in very deficient individuals, or in those receiving daily or weekly regimens.
A third potential limitation relates to the fact that data relating to adherence to study medication were not
available for all subjects. However, inclusion of non-adherent participants would bias the results of our
intention-to-treat analysis towards the null: thus, we conclude that effects of vitamin D in those who are
fully adherent to supplementation will be no less than those reported for the study population overall. Our
definition of ARI was wide, incorporating both URI and LRI and, consequently, our overall findings cannot
necessarily be generalised to specific ARIs (e.g. those confined to a specific anatomical site or caused by a
single pathogen). Finally, we caution that virological, microbiological and/or radiological confirmation was
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obtained for a minority of ARI events. ARI is often a clinical diagnosis in practice, however, and, as all studies
were double-blind and placebo-controlled, differences in incidence of events between study arms cannot be
attributed to observation bias.
Future research
Incorporation of additional IPD from ongoing trials in the field has the potential to increase the statistical
power of subgroup analyses; this IPD meta-analysis should therefore be updated when a significant new
body of data has accumulated. Given the major impact of ARIs on economic productivity and health-care
use, our findings are likely to influence the economic case for the introduction of vitamin D fortification of
foods in the UK. Economic models of the cost-effectiveness of vitamin D fortification in the UK should
therefore be updated to take account of the previously unappreciated protective effects of vitamin D
against ARIs. Such models will need to be populated with accurate data regarding vitamin D intake and
the prevalence of vitamin D deficiency in the general population and in subpopulations deemed to be at
particular risk of vitamin D deficiency, intake of vitamin D-fortifiable foods and drinks in these populations,
attitudes towards different fortification strategies (mandatory vs. voluntary) and the costs of adverse health
outcomes such as fractures, falls and ARIs that could be reduced by realising improvements in population
vitamin D status. Such modelling would also need to take into account differential profiles of URI compared
with LRI in terms of frequency, severity and heath-care costs.
Conclusions
Our synthesis of the current evidence suggests that vitamin D supplementation can prevent ARI, broadly
defined. We identified that the greatest potential benefit is for those individuals who are very deficient
in vitamin D. Those receiving daily or weekly supplementation without additional bolus doses also
experienced particular benefit. Our results add to the body of evidence supporting the introduction of
public health measures, such as food fortification, to improve vitamin D status in settings in which
profound vitamin D deficiency is common.
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Appendix 1 Electronic search strategy
The full electronic search strategy for MEDLINE is presented.
Cochrane highly sensitive search strategy for identifying randomised
controlled trials
#1. randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab]
OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]
#2. animals [mh] NOT humans [mh]
#3. #1 NOT #2
Terms specific to vitamin D
#4. Vitamin D OR vitamin D2 OR vitamin D3 OR cholecalciferol OR ergocalciferol OR alphacalcidol OR
alfacalcidol OR calcitriol OR paricalcitol OR doxerocalciferol
Terms specific to acute respiratory infection
#5. Acute Respiratory Infection OR Upper Respiratory Infection OR Lower Respiratory Infection OR Respiratory
Tract Infection OR Common Cold OR Sinusitis OR Pharyngitis OR Laryngitis OR Laryngotracheobronchitis OR
Tonsillitis OR peritonsillar abscess OR Croup OR Epiglottitis OR supraglottitis OR Otitis Media OR Pneumonia
OR Bronchopneumonia OR Bronchitis OR Pleurisy OR Pleuritis
Terms specific to asthma
#6 Asthma OR bronchial hyperreactivity OR bronchial hyper-reactivity OR respiratory hypersensitivity OR
reactive airway
Terms specific to chronic obstructive pulmonary disease
#7 Chronic obstructive pulmonary disease OR COPD OR COAD OR emphysema OR chronic bronchitis OR
AECB OR AECOPD
Combination of terms to identify randomised controlled trials of vitamin D for the
prevention of acute respiratory infection
#3 AND #4 AND #5
Combination of terms to identify randomised controlled trials of vitamin D conducted in
patients with asthma
#3 AND #4 AND #6
Combination of terms to identify randomised controlled trials of vitamin D conducted in
patients with chronic obstructive pulmonary disease
#3 AND #4 AND #7
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